202 related articles for article (PubMed ID: 23396091)
21. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
22. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.
Schickli JH; Whitacre DC; Tang RS; Kaur J; Lawlor H; Peters CJ; Jones JE; Peterson DL; McCarthy MP; Van Nest G; Milich DR
J Clin Invest; 2015 Apr; 125(4):1637-47. PubMed ID: 25751145
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
24. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection.
Rodriguez-Fernandez R; Mejias A; Ramilo O
Pediatr Infect Dis J; 2021 May; 40(5S):S35-S39. PubMed ID: 34042909
[TBL] [Abstract][Full Text] [Related]
27. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.
Schuster JE; Cox RG; Hastings AK; Boyd KL; Wadia J; Chen Z; Burton DR; Williamson RA; Williams JV
J Infect Dis; 2015 Jan; 211(2):216-25. PubMed ID: 24864121
[TBL] [Abstract][Full Text] [Related]
28. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein.
Bergeron HC; Murray J; Arora A; Nuñez Castrejon AM; DuBois RM; Anderson LJ; Kauvar LM; Tripp RA
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243153
[TBL] [Abstract][Full Text] [Related]
29. Respiratory syncytial virus disease: prevention and treatment.
Chu HY; Englund JA
Curr Top Microbiol Immunol; 2013; 372():235-58. PubMed ID: 24362693
[TBL] [Abstract][Full Text] [Related]
30. Effect of digestion on stability of palivizumab IgG1 in the infant gastrointestinal tract.
Lueangsakulthai J; Kim BJ; Demers-Mathieu V; Sah BNP; Woo Y; Olyaei A; Aloia M; O'Connor A; Scottoline BP; Dallas DC
Pediatr Res; 2021 Aug; 90(2):335-340. PubMed ID: 33214672
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
32. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
34. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.
Makari D; Checchia PA; Devincenzo J
Hum Vaccin Immunother; 2014; 10(3):607-14. PubMed ID: 24316863
[TBL] [Abstract][Full Text] [Related]
35. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.
Tiwari PM; Vanover D; Lindsay KE; Bawage SS; Kirschman JL; Bhosle S; Lifland AW; Zurla C; Santangelo PJ
Nat Commun; 2018 Oct; 9(1):3999. PubMed ID: 30275522
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
[TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
[TBL] [Abstract][Full Text] [Related]
38. RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.
Hervé PL; Deloizy C; Descamps D; Rameix-Welti MA; Fix J; McLellan JS; Eléouët JF; Riffault S
Nanomedicine; 2017 Feb; 13(2):411-420. PubMed ID: 27553073
[TBL] [Abstract][Full Text] [Related]
39. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
40. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
